Aethlon Medical Q2 operating expenses drop

Aethlon Medical

12/11/2025 21:46

Corrects operating expenses period in Key Details table to Q2 from Q3

Overview

Aethlon fiscal Q2 operating expenses drop 48% yr/yr, reflecting disciplined cost management

Outlook

Company did not provide specific financial guidance for future quarters in its press release

Co says clinical and research progress continues alongside substantial cost reductions

Result Drivers

COST REDUCTIONS - Operating expenses decreased by 48% due to disciplined cost management, including lower headcount and reduced clinical trial costs

REDUCED GENERAL AND ADMINISTRATIVE EXPENSES - Declined by approximately $437,000 driven by lower clinical trial costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Operating Expenses
$1.5 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Aethlon Medical Inc is $12.38, about 64.9% above its November 11 closing price of $4.34

Press Release: ID:nPn3H6pjDa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)